Drug Combination Details
| General Information of the Combination (ID: C43351) | |||||
|---|---|---|---|---|---|
| Name | Xanthohumol NP Info | + | Praziquantel Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CD44 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TFRC | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Six- to eight-week-old male Syrian golden hamsters were used in this study. | |||||
| Experimental
Result(s) |
XN administered in combination with PZ could efficiently prevent CCA development and hence provide potential chemopreventive benefits in Ov-induced cholangiocarcinogenesis. | |||||
